Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Cagrilintide/semaglutide

A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight

Novo Nordisk · Phase 3 · Completed · Enrollment 331

NCT05813925

Participants reaching a weight loss threshold

Participants reaching threshold, %

Source: Cited trial source. The denominator is the source figure, when it states one.

No selected arm reports a responder percent.

Show as table
Arm≥5%≥10%≥15%≥20%
CagriSema 2.4 mg/2.4 mgn/rn/rn/rn/r
Semaglutide 2.4 mgn/rn/rn/rn/r

Not shown

  • CagriSema 2.4 mg/2.4 mg: endpoint not reported
  • Semaglutide 2.4 mg: endpoint not reported